Articles from NeuroOne Medical Technologies Corporation

Study Reports Immediate Pain Freedom in 14 of 15 Patients; all Patients Achieved Favorable Pain Outcomes at a Mean Six-Month Follow-Up

NeuroOne’s FDA 510(k)-Cleared OneRF Trigeminal Nerve Ablation System Offers Hope for Patients Suffering from Trigeminal Neuralgia

Major Commercial Milestone Represents Important Step Toward Potential Long-Term Collaborations with Global Pharmaceutical Companies

New NIH Award will Initially Provide NeuroOne Approximately $200,000 through April 2027

Preliminary Fiscal Q4 2026 Product Revenue of $3.8 Million

Agreement Covers Key Southern California Counties Including Los Angeles Metro as NeuroOne Broadens Commercial Access in Key U.S. Markets